ZL-2306(nirapairb) + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer
Conditions
Extensive-stage Small Cell Lung Cancer
Trial Timeline
Aug 20, 2018 → Mar 20, 2020
NCT ID
NCT03516084About ZL-2306(nirapairb) + Placebo
ZL-2306(nirapairb) + Placebo is a phase 3 stage product being developed by Zai Lab for Extensive-stage Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03516084. Target conditions include Extensive-stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 6 similar drugs in Extensive-stage Small Cell Lung Cancer were approved
Approved (0) Terminated (0) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03516084 | Phase 3 | Terminated |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer